Genetic breakthroughs could point pharma to a long COVID drug

The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

By Kelly Bilodeau • April 22, 2025

Can anything threaten Novo and Lilly’s obesity market dominance?

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

By Amy Baxter • April 21, 2025

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

How a scrapped Pfizer drug became a winner for SpringWorks

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

By Alexandra Pecci • April 21, 2025

A big moment is coming for psychedelics

Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

By Meagan Parrish • April 18, 2025

Amid an onshoring push, Raleigh is poised to be pharma’s next manufacturing hub

Lower operating costs and a supply of high-skilled workers are helping the North Carolina region pull in billions of pharma manufacturing investments. 

By Alexandra Pecci • April 16, 2025

US risks losing biotech edge to China, report warns

“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S. to invest at least $15 billion into the sector over the next five years.

By Ned Pagliarulo • April 9, 2025

Big Pharma is rewriting the R&D playbook to account for seismic shifts in the investment landscape

The top 20 pharma companies are focusing on novel drugs, innovative dealmaking and playing to their strengths to bolster R&D ROI.

By Alexandra Pecci • April 9, 2025

Her son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.

Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.

By Michael Gibney • April 8, 2025

US vs. EU: When it comes to novel Alzheimer’s drugs, regulators can’t seem to agree

The FDA is much more flexible in approving first-in-class drugs compared to European regulators.  

By Amy Baxter • April 7, 2025

A birth control pill for men makes moves in the clinic

So far, the science and safety seem solid. But is the world emotionally ready to shift the responsibility of contraception to men?

By Kelly Bilodeau • April 7, 2025

The year’s biggest biotech haul shows investors are still chasing the AI dream

Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.

By Meagan Parrish • April 4, 2025

Industry leaders react to HHS being ‘reduced to a shell’

What healthcare watchdogs have said about the far-reaching job cuts this week.

By Meagan Parrish and Amy Baxter • April 3, 2025

With government health info in limbo, drugmakers lose credible sources

The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

By Alexandra Pecci • April 1, 2025

Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’

Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.

By Michael Gibney • April 1, 2025

A recent gene therapy death shines a light on AAV safety

This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

By Kelly Bilodeau • March 31, 2025

In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.  

By Amy Baxter • March 31, 2025

Harnessing the power of AI to detect ATTR-CM

From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

March 31, 2025

FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.

By Meagan Parrish • March 28, 2025

HHS announces sweeping reorganization, including cuts of 10K workers

Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.

By Rebecca Pifer • March 27, 2025

How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

By Michael Gibney • March 27, 2025

Biogen plots new global headquarters in Kendall Square

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

By Jacob Bell • March 25, 2025

The industry heavyweight behind Novavax’s push to bounce back

As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.

By Alexandra Pecci • March 25, 2025

Biotechs emerging from stealth take aim at pharma’s prime targets

The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

By Kelly Bilodeau • March 24, 2025

How pharma could feel the pain of a recession

Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.

By Meagan Parrish • March 21, 2025

Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

By Michael Gibney • March 20, 2025